Vanda Pharmaceuticals (VNDA) Receivables - Net (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Receivables - Net data on file, last reported at $56.9 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 27.52% year-over-year to $56.9 million; the trailing twelve-month figure through Mar 2026 stood at $56.9 million (up 27.52% YoY), and the FY2025 full-year result was $54.6 million, up 15.87% from the prior year.
• Receivables - Net improved to $56.9 million in Q1 2026, from $54.6 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $56.9 million in Q1 2026 to a low of $24.5 million in Q1 2023.
• A 5-year average of $39.0 million and a median of $36.7 million in 2024 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net dropped 29.27% in 2022 and soared 49.77% in 2024, its largest moves.
• Tracing VNDA's Receivables - Net over 5 years: stood at $33.5 million in 2022, then increased by 1.92% to $34.2 million in 2023, then surged by 37.9% to $47.1 million in 2024, then grew by 15.87% to $54.6 million in 2025, then climbed by 4.22% to $56.9 million in 2026.
• Business Quant data shows VNDA's Receivables - Net at $56.9 million in Q1 2026, $54.6 million in Q4 2025, and $50.5 million in Q3 2025.